NCT04774380 (LUMINANCE) is a Phase 3 clinical trial of Durvalumab in Extensive-stage Small Cell Lung Cancer, sponsored by AstraZeneca.

Who is sponsoring NCT04774380?

NCT04774380 is sponsored by AstraZeneca.

What drugs are being tested in NCT04774380?

Interventions in NCT04774380: Durvalumab, Cisplatin, Carboplatin, Etoposide.

What condition does NCT04774380 study?

NCT04774380 studies Extensive-stage Small Cell Lung Cancer.

Is NCT04774380 still recruiting?

NCT04774380 is currently completed. Last updated 23 May 2025.

Are results published for NCT04774380?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-05-23 · How we verify

NCT04774380: LUMINANCE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer

Completed Phase 3 Results posted Last updated 23 May 2025

What this trial tests

Phase 3 trial testing Durvalumab in Extensive-stage Small Cell Lung Cancer in 152 participants. Completed in 2 January 2025.

Timeline

11 November 2021

Primary endpoint
12 June 2023

2 January 2025

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	152
Start date	11 November 2021
Primary completion	12 June 2023
Estimated completion	2 January 2025
Sites	35 locations across Italy, Germany, Canada, Bulgaria, Turkey (Türkiye), Czechia

Drugs / interventions tested

Durvalumab — full drug profile →
Cisplatin (cisplatin) — full drug profile →
Carboplatin (Carboplatin) — full drug profile →
Etoposide (etoposide) — full drug profile →

Conditions studied

Extensive-stage Small Cell Lung Cancer — all drugs for Extensive-stage Small Cell Lung Cancer →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 130, any sex, with Extensive-stage Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Incidence of Grade 3 or Higher Adverse Events (AEs) Primary · From first dose of study treatment until 90 days after treatment discontinuation, up to 2.5 years.

Incidence of Grade 3 or higher adverse events to evaluate safety and tolerability profile of durvalumab + Platinum (cisplatin or carboplatin) plus etoposide (EP) treatment was assessed.

Group	Value	95% CI
Durvalumab+EP	91

Number of Participants With Incidence of Immune Mediated Adverse Events (imAEs) Primary · From first dose of study treatment until 90 days after treatment discontinuation, up to 2.5 years.

Immune mediated adverse events (imAEs) were assessed to evaluate safety and tolerability profile of durvalumab + EP treatment. An imAE is defined as an AESI that is associated with drug exposure and is consistent with an immune-mediated mechanism of action (MOA) and where there is no clear alternate etiology.

Group	Value	95% CI
Durvalumab+EP	22

Progression-free Survival (PFS) Secondary · From first dose of study treatment until disease progression or death, up to 2.5 years.

Efficacy of durvalumab + EP treatment by evaluating PFS according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) was assessed. The PFS is the time from the first date of treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from Investigational medicinal product (IMP) or received another anticancer therapy prior to progression.

Group	Value	95% CI
Durvalumab+EP	6.3	5.75 – 6.47

Percentage of Participants Alive and Progression-free at 12 Months From First Date of Treatment (PFS12) Secondary · From first date of study treatment until 12 months.

The efficacy of durvalumab + EP treatment by evaluating PFS12 according to RECIST 1.1 was assessed.

Group	Value	95% CI
Durvalumab+EP	15.0	9.76 – 21.21

Objective Response Rate (ORR) Secondary · From screening until disease progression or the last evaluable assessment in the absence of progression, up to 2.5 years.

The efficacy of durvalumab + EP treatment by evaluating ORR according to RECIST 1.1 was assessed. The ORR will be assessed based on Investigator-assessed response to treatment of complete response (CR) and partial response (PR), per RECIST1.1.

Group	Value	95% CI
Durvalumab+EP	66.4	58.3 – 73.9

Duration of Response (DoR) Secondary · From the date of first documented response until the first date of documented progression or death in the absence of disease progression, up to 2.5 years.

The efficacy of durvalumab + EP treatment by evaluating DoR according to RECIST 1.1 was assessed. The DoR is time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression.

Group	Value	95% CI
Durvalumab+EP	5.2	5.03 – 5.59

Percentage of Participants Remaining in Response, 12 Months After First Documented Objective Response (DoR12) Secondary · From the date of first documented response until the first date of documented progression or death in the absence of disease progression, up to 2.5 years.

The efficacy of durvalumab + EP treatment by evaluating DoR12 according to RECIST 1.1 was assessed.

Group	Value	95% CI
Durvalumab+EP	19.8	12.70 – 28.06

Overall Survival (OS) Secondary · From first dose of study treatment to death, up to 2.5 years.

Assessment of the efficacy of durvalumab + EP treatment by evaluating OS. The OS is the time from the first date of treatment until death due to any cause.

Group	Value	95% CI
Durvalumab+EP	16.4	12.45 – 18.73

Percentage of Participants Alive at 12 Months From First Date of Treatment (OS12) Secondary · From first dose of study treatment till 12 months.

The efficacy of durvalumab + EP treatment by evaluating OS12 was assessed.

Group	Value	95% CI
Durvalumab+EP	59.8	51.00 – 67.55

Number of Participants With Adverse Events and Serious Adverse Events Secondary · From first dose of study treatment until 90 days after discontinuation, up to 2.5 years.

To evaluate safety and tolerability profile of durvalumab + EP treatment, adverse events and serious adverse events were assessed.

Any Adverse event (AE)

Group	Value	95% CI
Durvalumab+EP	142

Any AE possibly related to any treatment

Group	Value	95% CI
Durvalumab+EP	109

Any AE of maximum CTCAE grade 3 or grade 4

Group	Value	95% CI
Durvalumab+EP	85

Any AE of maximum CTCAE grade 3 or grade 4, possibly related to any treatment

Group	Value	95% CI
Durvalumab+EP	59

Any AE with outcome of death

Group	Value	95% CI
Durvalumab+EP	15

Any AE with outcome of death, possibly related to any treatment

Group	Value	95% CI
Durvalumab+EP	4

Any AE with outcome of death, possibly related to durvalumab

Group	Value	95% CI
Durvalumab+EP	0

Any AE with outcome of death, possibly related to EP

Group	Value	95% CI
Durvalumab+EP	4

Number of Participants With Adverse Events of Special Interests Secondary · From first dose of study treatment until 90 days after discontinuation, up to 2.5 years.

To evaluate safety and tolerability profile of durvalumab + EP treatment, adverse events of special interests were assessed. An AESI is an AE of scientific and medical interest specific to understanding of the IMP. AESIs for durvalumab include, but are not limited to, events with a potential inflammatory or immune-mediated mechanism and which may require more frequent monitoring and/or interventions such as steroids, immunosuppressants, and/or hormone replacement therapy. This includes adverse events of special/ possible interest.

Group	Value	95% CI
Durvalumab+EP	82

Adverse events — posted to ClinicalTrials.gov

Time frame: From first dose of study treatment until 90 days after treatment discontinuation, up to 2.5 years.. Reporting threshold: 0.03%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Durvalumab+EP

Serious: 52/152 (34%)

Deaths: 85/152

Serious adverse events (65 terms)

Reaction	System	Durvalumab+EP
Pneumonia	Infections and infestations	—
Hyponatraemia	Metabolism and nutrition disorders	—
Acute kidney injury	Renal and urinary disorders	—
Anaemia	Blood and lymphatic system disorders	—
Leukopenia	Blood and lymphatic system disorders	—
Hyperglycaemia	Metabolism and nutrition disorders	—
Abdominal pain upper	Gastrointestinal disorders	—
Platelet count decreased	Investigations	—
Sepsis	Infections and infestations	—
Febrile neutropenia	Blood and lymphatic system disorders	—
Thrombocytopenia	Blood and lymphatic system disorders	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	—
Constipation	Gastrointestinal disorders	—
Abdominal infection	Infections and infestations	—
COVID-19 pneumonia	Infections and infestations	—
Lower respiratory tract infection	Infections and infestations	—
Postoperative wound infection	Infections and infestations	—
Tooth abscess	Infections and infestations	—
Urinary tract infection bacterial	Infections and infestations	—
Neutropenia	Blood and lymphatic system disorders	—
Acidosis	Metabolism and nutrition disorders	—
Hypernatraemia	Metabolism and nutrition disorders	—
Hyperphosphataemia	Metabolism and nutrition disorders	—
Hypokalaemia	Metabolism and nutrition disorders	—

Other adverse events (57 terms — click to expand)

Reaction	System	Durvalumab+EP
Anaemia	Blood and lymphatic system disorders	—
Neutropenia	Blood and lymphatic system disorders	—
Nausea	Gastrointestinal disorders	—
Constipation	Gastrointestinal disorders	—
Thrombocytopenia	Blood and lymphatic system disorders	—
Fatigue	General disorders	—
Alopecia	Skin and subcutaneous tissue disorders	—
Leukopenia	Blood and lymphatic system disorders	—
Hypomagnesaemia	Metabolism and nutrition disorders	—
Hyperthyroidism	Endocrine disorders	—
Hypothyroidism	Endocrine disorders	—
Blood creatinine increased	Investigations	—
White blood cell count decreased	Investigations	—
Hyponatraemia	Metabolism and nutrition disorders	—
Cough	Respiratory, thoracic and mediastinal disorders	—
Gamma-glutamyltransferase increased	Investigations	—
Neutrophil count decreased	Investigations	—
Aspartate aminotransferase increased	Investigations	—
Upper respiratory tract infection	Infections and infestations	—
Decreased appetite	Metabolism and nutrition disorders	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—
Diarrhoea	Gastrointestinal disorders	—
Pyrexia	General disorders	—
Alanine aminotransferase increased	Investigations	—
Platelet count decreased	Investigations	—
Headache	Nervous system disorders	—
COVID-19	Infections and infestations	—
Hypoalbuminaemia	Metabolism and nutrition disorders	—
Hypokalaemia	Metabolism and nutrition disorders	—
Arthralgia	Musculoskeletal and connective tissue disorders	—
Asthenia	General disorders	—
Blood alkaline phosphatase increased	Investigations	—
Dyspepsia	Gastrointestinal disorders	—
Amylase increased	Investigations	—
Blood lactate dehydrogenase increased	Investigations	—
Hypocalcaemia	Metabolism and nutrition disorders	—
Dizziness	Nervous system disorders	—
Stomatitis	Gastrointestinal disorders	—
Vomiting	Gastrointestinal disorders	—
Weight decreased	Investigations	—

Most-reported serious reactions: Pneumonia, Hyponatraemia, Acute kidney injury, Anaemia, Leukopenia, Hyperglycaemia, Abdominal pain upper, Platelet count decreased.

Data from ClinicalTrials.gov NCT04774380 adverse events section.

Sponsor's own description

Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Platinum and Palladium Complexes as Promising Sources for Antitumor Treatments.
Czarnomysy R, Radomska D, Szewczyk OK, Roszczenko P, et al · · 2021 · cited 47× · PMID 34361037 · DOI 10.3390/ijms22158271
Synergistic Action of Immunotherapy and Nanotherapy against Cancer Patients Infected with SARS-CoV-2 and the Use of Artificial Intelligence.
Gupta T, Debele TA, Wei YF, Gupta A, et al · · 2022 · cited 1× · PMID 35008377 · DOI 10.3390/cancers14010213

Verify or expand the search:

Other trials of Durvalumab

Trials testing the same drug.

NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting

Other recruiting trials for Extensive-stage Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06479473 — Radiotherapy to All Residual Lesions After Chemoimmunotherapy · Phase 1, PHASE2 · recruiting
NCT04397003 — Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer · Phase 2 · active not recruiting
NCT04702880 — A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage · Phase 2 · active not recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04774380 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 23 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04774380.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing